References
- Erika V, Yuting M, Elisa E, Baracco AS, David PE, Federico P, Heng Y, Sandy A, Kariman C, Michaela S et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science (80-)[Internet] 2015; 350:972-8. Available from: http://www.sciencemag.org/content/early/2015/10/28/science.aad0779.full.pdf; PMID:26516201; http://dx.doi.org/10.1126/science.aad0779
- Haining WN, Neuberg DS, Keczkemethy HL, Evans JW, Rivoli S, Gelman R, Rosenblatt HM, Shearer WT, Guenaga J, Douek DC et al. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood [Internet] 2005; 106:1749-54. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895221/; PMID:15920008; http://dx.doi.org/10.1182/blood-2005-03-1082
- Sung L, Garnis A, Alonzo TA, Buxton A, Britton K, DeSwarte-Wallace J, Woods WG. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer 2009; 115:1100-8; PMID:19156894; http://dx.doi.org/10.1002/cncr.24107
- Turtle CJ, Swanson HM, Fujii N, Estey EH, Riddell SR. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity 2009; 31:834-44; PMID:19879163; http://dx.doi.org/10.1016/j.immuni.2009.09.015
- Dimeloe S, Frick C, Fischer M, Gubser PM, Razik L, Bantug GR, Ravon M, Langenkamp A, Hess C. Human regulatory T cells lack the cyclophosphamideextruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. Eur J Immunol 2014; 44:3614-20; PMID:25251877; http://dx.doi.org/10.1002/eji.201444879
- Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Maillard SA, Montandon N, Rufer N, Waldvogel S, Delorenzi M et al. Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. Sci Transl Med [Internet] 2015; 7:282ra48-282ra48. Available from http://stm.sciencemag.org/content/7/282/282ra48.abstract; PMID:25855494; http://dx.doi.org/10.1126/scitranslmed.aaa3700
- Ge Q, Hu H, Eisen HN, Chen J. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. PNAS 2002; 99:2989-94; PMID:11880642; http://dx.doi.org/10.1073/pnas.052714099
- Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI, Surh CD. IL-7 is critical for homeostatic proliferation and survival of naive T cells. PNAS 2001; 98:8732-7; PMID:11447288; http://dx.doi.org/10.1073/pnas.161126098
- Kim K, Lee C, Sayers TJ, Muegge K, Durum SK. The trophic action of IL-7 on pro-T cells: inhibition of apoptosis of Pro-T1, -T2, and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J Immunol [Internet] 1998; 160:5735–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9637482; PMID:9637482
- Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsemeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature [Internet] 2003; 426:671-6. Available from:http://www.nature.com/nature/journal/v426/n6966/abs/nature02166.html; PMID:14668867; http://dx.doi.org/10.1038/nature02067
- Li WQ, Jiang Q, Khaled AR, Keller JR, Durum SK. Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. J Biol Chem [Internet] 2004; 279:29160-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15123689; PMID:15123689; http://dx.doi.org/10.1074/jbc.M401656200
- Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naïve cells into memory-phenotype cells. Nat Immunol 2011; 12:478-84; PMID:21739670; http://dx.doi.org/10.1038/ni.2018
- Swain SL, Hu H, Huston G. Class II-independent generation of CD4 memory T cells from effectors. Science 1999; 286:1381-3; PMID:10558997; http://dx.doi.org/10.1126/science.286.5443.1381
- Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science 1999; 286:1377-81; PMID:10558996; http://dx.doi.org/10.1126/science.286.5443.1377
- Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8:591-9; PMID:9620680; http://dx.doi.org/10.1016/S1074-7613(00)80564-6
- Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science (80-) 2000; 288:675-8; PMID:10784451; http://dx.doi.org/10.1126/science.288.5466.675
- Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med [Internet] 2000; 191:771-80. Available from:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2195858&tool=pmcentrez&rendertype=abstract; PMID:10704459; http://dx.doi.org/10.1084/jem.191.5.771
- Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, Ahmed R. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med [Internet] 2002; 195:1541-8. Available from: http://www.jem.org/cgi/doi/10.1084/jem.20020369; PMID:12070282; http://dx.doi.org/10.1084/jem.20020369
- Tan JT. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med [Internet] 2002; 195:1523-32. Available from: http://www.jem.org/cgi/doi/10.1084/jem.20020066; PMID:12070280; http://dx.doi.org/10.1084/jem.20020066
- Marrack P, Kappler J. Control of T cell viability. Annu Rev Immunol 2004; 22:765-87; PMID:15032596; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104554
- Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett [Internet] 2010; 127:85-92. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2808451&tool=pmcentrez&rendertype=abstract; PMID:19818367; http://dx.doi.org/10.1016/j.imlet.2009.09.009
- Stonier SW, Ma LJ, Castillo EF, Schluns KS. Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood [Internet] 2008; 112:4546-54. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2597127&tool=pmcentrez&rendertype=abstract; PMID:18812469; http://dx.doi.org/10.1182/blood-2008-05-156307
- Ramsey C, Rubinstein MP, Kim DM, Cho J, Sprent J, Surh CD. The lymphopenic environment of CD132 (common gamma chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol 2008; 180:5320-6; PMID:18390713; http://dx.doi.org/10.4049/jimmunol.180.8.5320
- Kieper WCW, Troy A, Burghardt JT, Ramsey C, Lee JY, Jiang H-Q, Dummer W, Shen H, Cebra JJ, Surh CD. Cutting edge: recent immune status determines the source of antigens that drive homeostatic T cell expansion. J Immunol [Internet] 2005; 174:3158-63. Available from:http://www.jimmunol.org/content/174/6/3158.abstract\nhttp://www.jimmunol.org/content/174/6/3158.short; PMID:15749843; http://dx.doi.org/10.4049/jimmunol.174.6.3158
- Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, Wood LV, Yarchoan R, Zuckerman J et al. A potential role for interleukin-7 in T-cell homeostasis. Blood [Internet] 2001; 97:2983-90. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11342421; PMID:11342421; http://dx.doi.org/10.1182/blood.V97.10.2983
- Sheikh V, Porter BO, DerSimonian R, Kovacs SB, Thompson WL, Perez-Diez A, Freeman AF, Roby G, Mican J, Pau A et al. Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia. Blood [Internet] 2015; 127:977-88. Available from: http://www.bloodjournal.org/content/127/8/977.abstract; PMID:26675348; http://dx.doi.org/10.1182/blood-2015-05-645077
- Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009; 69:5383-91; PMID:19549917; http://dx.doi.org/10.1158/0008-5472.CAN-08-3845
- Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (80- ) 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
- Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-57; PMID:15800326; http://dx.doi.org/10.1200/JCO.2005.00.240
- Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest [Internet] 2002; 110:185-92. Available from:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12122110\nhttp://www.jci.org/articles/view/15175/files/pdf?disposition=attachment; PMID:12122110; http://dx.doi.org/10.1172/JCI0215175
- Gao J, Zhao L, Wan YY, Zhu B. Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy. Int J Mol Sci 2015; 16:10267-80; PMID:25955647; http://dx.doi.org/10.3390/ijms160510267
- Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010; 16:727-35; PMID:20068111; http://dx.doi.org/10.1158/1078-0432.CCR-09-1303
- Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Maryalice Stetler-Stevenson KEM, Mavroukakis SA, Morre M, Buffet R et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-9; PMID:16699374; http://dx.doi.org/10.1097/01.cji.0000210386.55951.c2
- Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med [Internet] 2008; 205:1701-14. Available from:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442646/pdf/jem2051701.pdf; PMID:18573906; http://dx.doi.org/10.1084/jem.20071681
- Okamoto Y, Douek DC, McFarland RD, Koup RA. Effects of exogenous interleukin-7 on human thymus function. Blood 2002; 99:2851-8; PMID:11929775; http://dx.doi.org/10.1182/blood.V99.8.2851
- Suzuki T, Kishimoto H, Abe R. Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model. Cancer Immunol Immunother [Internet] 2016; 65:341-54. Available from: http://link.springer.com/10.1007/s00262-016-1808-7; PMID:26880265; http://dx.doi.org/10.1007/s00262-016-1808-7
- Mueller K, Schweier O, Pircher H. Efficacy of IL-2- vs. IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur J Immunol [Internet] 2008; 38:2874-85. Available from: http://doi.wiley.com/10.1002/eji.200838426; PMID:18825743; http://dx.doi.org/10.1002/eji.200838426
- Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA, Morris JC. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res [Internet] 2010; 70:1072-81. Available from: http://cancerres.aacrjournals.org/content/70/3/1072.full; PMID:20086176; http://dx.doi.org/10.1158/0008-5472.CAN-09-1301
- Kaiser AD, Gadiot J, Guislain A, Blank CU. Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts. Cancer Immunol Immunother 2013; 62:503-15; PMID:23001162; http://dx.doi.org/10.1007/s00262-012-1350-1
- Sadelain M. CAR therapy: The CD19 paradigm. J Clin Invest 2015; 125:3392-400; PMID:26325036; http://dx.doi.org/10.1172/JCI80010
- Maus MV, June CH. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res [Internet] 2016; 22:1875-84. Available from: http://clincancerres.aacrjournals.org/content/22/8/1875.abstract; PMID:27084741; http://dx.doi.org/10.1158/1078-0432.CCR-15-1433
- Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia [Internet] 2010; 24:1160-70. Available from:http://www.ncbi.nlm.nih.gov/pubmed/20428207; PMID:20428207; http://dx.doi.org/10.1038/leu.2010.75
- North BYRJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 55:1063-74; PMID:6460831; http://dx.doi.org/10.1084/jem.155.4.1063
- Le Campion A, Pommier A, Delpoux A, Stouvenel L, Auffray C, Martin B, Lucas B. IL-2 and IL-7 determine the homeostatic balance between the regulatory and conventional CD4+ T cell compartments during peripheral T cell reconstitution. J Immunol [Internet] 2012; 189:3339-46. Available from:http://www.ncbi.nlm.nih.gov/pubmed/22933631; PMID:22933631; http://dx.doi.org/10.4049/jimmunol.1103152
- Bolton HA, Zhu E, Terry AM, Guy TV, Koh WP, Tan SY, Power CA, Bertolino P, Lahl K, Sparwasser T et al. Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease. J Clin Invest 2015; 125:3627-41; PMID:26301814; http://dx.doi.org/10.1172/JCI76031
- Peffault de Latour R, Dujardin HC, Mishellany F, Burlen-Defranoux O, Zuber J, Marques R, Di Santo J, Cumano A, Vieira P, Bandeira A. Ontogeny, function, and peripheral homeostasis of regulatory T cells in the absence of interleukin-7. Blood [Internet] 2006; 108:2300-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16763207; PMID:16763207; http://dx.doi.org/10.1182/blood-2006-04-017947
- Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (80-) [Internet] 2013; 342:971-6. Available from: http://science.sciencemag.org/content/342/6161/971.abstract; PMID:24264990; http://dx.doi.org/10.1126/science.1240537
- Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten Ra, Molina Da, Salcedo R, Back T, Cramer S et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (80-) [Internet] 2013; 342:967-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24264989; PMID:24264989; http://dx.doi.org/10.1126/science.1240527
- Abu Eid R, Razavi GSE, Mkrtichyan M, Janik J, Khleif SN. Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res [Internet] 2016; 4:377-82. Available from:http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-16-0048; PMID:27196429; http://dx.doi.org/10.1158/2326-6066.CIR-16-0048
- Machiels JH, Reilly RT, Emens LA, Vaccines W, Tolerized H-, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice cyclophosphamide, doxorubicin, and paclitaxel enhance. Cancer Res 2001; 61:3689-97; PMID:11325840